Tasly shareholders back plan to invest idle funds in wealth management
Tasly Pharmaceutical Group Co., Ltd. held its fifth extraordinary general meeting of shareholders for 2025 on October 10, 2025, where shareholders approved the proposal to use idle funds for purchasing bank wealth management products. The resolution passed with a significant majority.
Of the total shares with voting rights, 659,271,256 votes were cast by 1,457 shareholders and proxies, representing 46.4520% of the company's total voting shares. The A-share vote count for the resolution was 626,053,129 in favor, constituting 94.9613% of the votes cast, while 32,850,267 votes were against (4.9828%), and 367,860 abstained (0.0559%).
For shareholders holding less than 5% of the shares, the resolution also received majority approval, with 25,280,094 votes in favor (43.2151%) and 32,850,267 votes against (56.1560%). The meeting was convened and presided over by chairwoman Zhou Hui, and a legal opinion issued by Inner Mongolia Jianzhong Law Firm confirmed the meeting's compliance with relevant laws and regulations.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Tasly Pharmaceutica Group publishes news
Free account required • Unsubscribe anytime